2024 Webinar: Revised Draft Appendix 1 of FDA’s Preventive Controls for Human Foods Guidance
The U.S. Food and Drug Administration (FDA) released the long-anticipated revised draft “Appendix 1” of the multi-chapter draft guidance for industry titled Hazard Analysis and Risk-Based Preventive Controls for Human Food: Draft Guidance for Industry on January 30, 2024. Since the initial publication of “Appendix 1”, many food industry groups, including ASTA, advocated for FDA to update the guidance to make corrections, reflect the latest scientific evidence, and minimize confusion and inconsistencies. The updated draft includes a number of notable revisions to potential hazards in spices and seasonings and guidance on hazard analysis for spices, including several updates that were requested by ASTA. The “Appendix 1” guidance has significant implications for FDA food facility inspections, as it is used as a key reference by inspectors. This 45-minute webinar provides the latest updates on how they may impact your food safety plan and facility inspections.
Membership Required
A valid ASTA membership is required to access this page. Please use the form below to log in with your ASTA member account.
Log in
Not a member yet? Click here to learn about joining ASTA today.
Related Resources
FDA Draft Guidance for Industry on Establishing Sanitation Programs for Low-Moisture Ready-to-Eat Human Foods Webinar
This webinar was presented by Maile Gradison, ASTA's General Counsel and partner at Hogan Lovells, and Anneke Altieri, Senior Associate with Hogan Lovells. The presentation will review FDA draft guidance published on January 6, 2025, intended to help manufacturers of Low-Moisture Ready-to-Eat (LMRTE) human foods, such as spices, establish sanitation programs and take appropriate corrective actions following a pathogen contamination event.
2015 Regulatory Presentation: FDA Criminal Enforcement Powers
This presentation was provided at the 2015 Regulatory Workshop in October. The presenter, Maile Gradison Hermida, presented on legal framework, FDA Enforcement powers, park doctrine, recent enforcement actions, and FSMA considerations.
